Home » Articles Posted by admin123

Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto

Vancouver, British Columbia – April 24, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune function in the targeted diseased organ, announced today it has opened two new clinical trial sites in Edmonton, Alberta and Toronto, Ontario to enroll participants in its Crohn’s […]

Qu Biologics Welcomes Gastroenterologist Dr. Remo Panaccione to IBD Advisory Team

Vancouver, British Columbia – December 4, 2014 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, is pleased to welcome gastroenterologist Dr. Remo Panaccione to its Inflammatory Bowel Disease (IBD) advisory team. Qu Biologics’ IBD advisory team provides guidance and […]

Qu Biologics’ Crohn’s Disease Clinical Trial Completes Independent Safety Review

Vancouver, British Columbia – October 29, 2014 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s immune system, announced that an independent Data Safety Monitoring Committee (DSMC) has reviewed the safety data generated from 30 patients (50% enrollment) from Qu Biologics’ current Crohn’s disease clinical trial […]

Qu Biologics to Present in Victoria, Kamloops, Calgary and Edmonton

Crohn’s and Colitis Canada – Western Canada invites you to an evening of inspiration and learning.  Dr. Hal Gunn, immune system expert and founder of Qu Biologics will present “The Immune System and Crohn’s Disease.”  Dr. Hal Gunn will present recent research in Crohn’s disease that has led to the discovery of the company’s investigational […]

Qu Biologics Presents Crohn’s Disease Compassionate Use Results at DDW

Vancouver, British Columbia – April 28, 2014 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system, announced that its abstract was selected for a poster presentation at the Digestive Diseases Week conference in Chicago, Illinois on May 4, 2014. Qu Biologics’ poster “Site Specific […]

Qu Biologics Opens Crohn’s Disease Clinical Trial to U.S. Participants

Vancouver, British Columbia – February 18, 2014 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune system, announced that its Crohn’s disease clinical trial is now accepting participants from the U.S. “Significant patient interest from the United States in our Crohn’s disease clinical trial […]

FREE SEMINAR: Microbial involvement in Crohn’s disease

Qu Biologics is pleased to welcome microbiology expert Dr. Brian Coombes to Vancouver to give a seminar on his recently published research in Nature Communications demonstrating that infection of mice with a strain of Crohn’s associated adherent-invasive E. coli leads to the development of intestinal inflammation in the mice which closely resembles human Crohn’s disease. […]

Gastroenterology Panel Discussion about the use of SSIs for Crohn’s disease

Listen to this informative panel discussion about the use of site specific immunomodulators (SSIs), an investigational treatment aimed at stimulating the immune system to reverse the chronic inflammation underlying Crohn’s disease. Panel includes: Gastroenterologist Dr. Brian Bressler, Principal Investigator of Qu Crohn’s Trial Qu Biologics’ founder and CEO, Dr. Hal Gunn Qu Biologics’ Chief Medical […]

Podcast: The Natural Health Show Special Report on Crohn’s December 7th & 8th

Update December 10th – Podcast of the show now available. Listen here. ______ Tune into The Natural Health Show this weekend for a special report on the impact of Crohn’s disease. Host Steve Herringer will interview Qu Crohn’s Trial Principal Investigator, Dr. Brian Bressler and Qu Biologics CEO, Dr. Hal Gunn. This segment will also feature […]

Travel Subsidy Now Offered to Crohn’s Trial Participants

Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system, announced that it has received ethics approval to implement a program to help subsidize travel and hotel costs for participants of its Crohn’s disease clinical trial. “In response to participant interest from across Canada we felt […]

1/212